Search Results - "Penault, F"

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I.T., Zackrisson, S., Senkus, E.

Get full text

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., Cardoso, F.

Get full text

Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective by Penault-Llorca, F, Viale, G

“…Triple-negative breast cancer (TNBC) is a heterogeneous disease diagnosed by immunohistochemistry and is characterised by tumours that do not express estrogen…”
Get full text

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I.T., Zackrisson, S., Senkus, E.

Get full text

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Senkus, E, Kyriakides, S, Penault-Llorca, F, Poortmans, P, Thompson, A, Zackrisson, S, Cardoso, F

Get full text

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer by Siena, S., Sartore-Bianchi, A., Marsoni, S., Hurwitz, H.I., McCall, S.J., Penault-Llorca, F., Srock, S., Bardelli, A., Trusolino, L.

“…Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using…”
Get full text

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer by Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., Penault-Llorca, F., Lantuéjoul, S.

“…Various programed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays have been developed and used in clinical trials in association with different drugs…”
Get full text

SA 8.1 Assessing HER2 heterogeneity by Penault-Llorca, F.

Get full text

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? by ARNOULD, L, GELLY, M, JEANNIN, J.-F, COUDERT, B, PENAULT-LLORCA, F, BENOIT, L, BONNETAIN, F, MIGEON, C, CABARET, V, FERMEAUX, V, BERTHEAU, P, GARNIER, J

“…This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with…”
Get full text

Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies by Jardé, T, Caldefie-Chézet, F, Goncalves-Mendes, N, Mishellany, F, Buechler, C, Penault-Llorca, F, Vasson, M P

“…Obesity is a risk factor for breast cancer development. A recent hypothesis suggests that the adipokines, adiponectin and leptin, are involved in breast cancer…”
Get full text

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer by Michiels, S., Pugliano, L., Marguet, S., Grun, D., Barinoff, J., Cameron, D., Cobleigh, M., Di Leo, A., Johnston, S., Gasparini, G., Kaufman, B., Marty, M., Nekljudova, V., Paluch-Shimon, S., Penault-Llorca, F., Slamon, D., Vogel, C., von Minckwitz, G., Buyse, M., Piccart, M.

“…The gold standard end point in randomized clinical trials in metastatic breast cancer (MBC) is overall survival (OS). Although therapeutics have been approved…”
Get full text

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer by Nabholtz, J.M., Chalabi, N., Radosevic‐Robin, N., Dauplat, M.M., Mouret‐Reynier, M.A., Van Praagh, I., Servent, V., Jacquin, JP, Benmammar, K.E., Kullab, S., Bahadoor, M.R.K., Kwiatkowski, F., Cayre, A., Abrial, C., Durando, X., Bignon, Y.J., Chollet, P., Penault‐Llorca, F.

“…Systemic therapy for triple negative breast cancer (TNBC) is mostly based upon chemotherapy. Epithelial Growth Factor Receptor (EGFR) is overexpressed in…”
Get full text

Impact of EGFR expression on colorectal cancer patient prognosis and survival by Spano, J.-P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., Attar, A., Benichou, J., Martin, A., Morere, J.-F., Raphael, M., Penault-Llorca, F., Breau, J.-L., Fagard, R., Khayat, D., Wind, P.

“…Background: Epidermal growth factor receptor (EGFR) is overexpressed in many types of cancers, especially colorectal cancer (CRC), and seems to reflect more…”
Get full text

Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases by Cutuli, B, Le-Nir, C. Cohen-Solal, Serin, D, Kirova, Y, Gaci, Z, Lemanski, C, De Lafontan, B, Zoubir, M, Maingon, P, Mignotte, H, Lara, C. Tunon de, Edeline, J, Penault-Llorca, F, Romestaing, P, Delva, C, Comet, B, Belkacemi, Y

“…Abstract Background Infiltrating MBC represents less than 1% of all male cancers. Our study details clinico-pathological features, treatments and prognostic…”
Get full text

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group by Dowsett, Mitch, Nielsen, Torsten O., A'Hern, Roger, Bartlett, John, Coombes, R. Charles, Cuzick, Jack, Ellis, Matthew, Henry, N. Lynn, Hugh, Judith C., Lively, Tracy, McShane, Lisa, Paik, Soon, Penault-Llorca, Frederique, Prudkin, Ljudmila, Regan, Meredith, Salter, Janine, Sotiriou, Christos, Smith, Ian E., Viale, Giuseppe, Zujewski, Jo Anne, Hayes, Daniel F.

“…Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment of the proportion of cells staining for the nuclear…”
Get full text

Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer by CHOLLET, P, AMAT, S, CURE, H, DE LATOUR, M, LE BOUEDEC, G, MOURET-REYNIER, M-A, FERRIERE, J-P, ACHARD, J-L, DAUPLAT, J, PENAULT-LLORCA, F

“…Only a few papers have been published concerning the incidence and outcome of patients with a pathological complete response after cytotoxic treatment in…”
Get full text

Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifen by Chene, G, Radosevic-Robin, N, Tardieu, A S, Cayre, A, Raoelfils, I, Dechelotte, P, Dauplat, J, Penault Llorca, F

“…Ovarian epithelial dysplasia was initially described in material from prophylactic oophorectomies for BReast CAncer gene (BRCA) mutation. Similar…”
Get full text

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes by Bidard, F.-C., Matthieu, M.-C., Chollet, P., Raoefils, I., Abrial, C., Dômont, J., Spielmann, M., Delaloge, S., André, F., Penault-Llorca, F.

“…We hypothesized that, among molecular subclasses of breast cancer, p53 status may have a differential predictive value for the efficacy of…”
Get full text

Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue by Jardé, T, Caldefie-Chézet, F, Damez, M, Mishellany, F, Perrone, D, Penault-Llorca, F, Guillot, J, Vasson, M P

Get full text

DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection by Matsuzaki, S., Canis, M., Vaurs-Barrière, C., Pouly, J.L., Boespflug-Tanguy, O., Penault-Llorca, F., Dechelotte, P., Dastugue, B., Okamura, K., Mage, G.

“…Endometriosis, a common gynecological disorder that causes infertility and pelvic pain, is defined as the presence of endometrial glands and stroma within…”
Get full text